-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] After ST Guanfu and Longshen Rongfa expected a net profit increase of more than 500% in the first half of the year, which attracted the attention of the industry, there is now another pharmaceutical company with a sharp increase in performance and a net profit increase of more than 20,000%, namely Jiu'an medic.
Jiu’an Medical announced on July 15 that it is expected that the net profit attributable to the parent in the first half of 2022 will be 11 billion yuan to 15 billion yuan, a year-on-year increase of 274636% to 28196
So, what kind of business is this? How to earn a lot of Jinpeng? According to the data, Jiu’an Medical is mainly engaged in the research and development, production and sales of health electronic products and smart hardwa.
The company focuses on the research and development, production and sales of household medical devices, as well as cloud platform systems and servic.
The main products are platforms for diabetic patients, and the main market is abro.
The self-test version of the antigen detection reagent developed by the company has successively obtained the certification of EU CE, German BfArM, Austrian BASG, Czech MZCR self-test whitelist, e.
, and can be sold in the above countri.
As for the reasons for the changes in performance in the first half of this year, Jiu'an Medical explained in the announcement that the company's iHealth kit products have obtained the FDA EUA authorization in the United States, and the company's own brand "iHealth" is used through the website of the US subsidiary and Amazon's US e-commerce platfo.
Carry out to C-side sales, and undertake government orders and commercial orders at the same ti.
Due to the substantial increase in the sales revenue of iHealth kit products during the reporting period, the company's performance during the reporting period also increased significantly compared with the same period last ye.
It is understood that on January 13 this year, iHealth LabsInc, a subsidiary of Jiu'an Medical, signed a "purchase contract" with ACC for Health kits, selling 250 million iHealth kit products to it, with a total contract price and tax of 275 billi.
US dollars (including shippin.
On January 26, iHealth US subsidiary signed a "Change Contract" with the American ACC on the original "Purchase Contrac.
On the basis of the purchase of 250 million iHealth kit products in the original contract, about 104 million additional iHealth kit products were purchas.
person, the total contract price and tax will increase by about 500 million US dollars (excluding freigh.
Driven by the antigen detection kit, the company achieved operating income of 2737 billion yuan in the first quarter of 2022, an increase of 66479% over the same period last year; net profit attributable to shareholders of listed companies was 1312 billion yuan, an increase of 375235% over the same period last ye.
According to statistics, the total profit of Jiu'an Medical in the past ten years (2012-2021) is only 940 million yuan, and the profit of Jiu'an Medical in one quarter of this year is about 15 times that of the total of the past ten yea.
In fact, it is not only the semi-annual and first quarter, but also the antigen detection kit product in the fourth quarter of 2021, which has enabled Jiu'an Medical to achieve a major reversal of its annual performan.
According to the financial report, Jiu’an Medical will achieve operating income of 397 billion yuan in 2021, a year-on-year increase of 136%; net profit attributable to shareholders of listed companies is 909 million yuan, a year-on-year increase of 279
Not long ago, Jiu'an Medical issued an announcement on the Shenzhen Stock Exchange's reply to the company's 2021 annual report inquiry lett.
The announcement shows that for the advantages compared with domestic and foreign companies in the same industry, Jiu'an Medical said that compared with domestic companies in the same industry, the company has advantages in access, brand and sales channels; compared with foreign companies in the same industry, the company It has large-scale supply capacity and marketing experience to C-end, and the production of the company's kits is domestic, which is more competitive in co.
Regarding the reasons for the high gross profit margin of the kit products and the commercial rationality, Jiu’an Medical stated that the iHealth kit product obtained the FDA EUA authorization in November 2021
There are fewer Chinese competitors in the North American market than in the European market, so companies can enjoy a certain access premi.
In addition, the company has formed a complete value chain from manufacturing to self-owned brand sales, with the iHealth brand premium advanta.
It is worth mentioning that the outbreak of the company's performance has also driven its stock price to rise all the w.
From November 1, 2021 to June 21, 2022, the share price of Jiu'an Medical rose 10176%, an increase of more than 10 tim.
As of the close on July 14, Jiu'an Medical's quotation was 651 yuan, an increase of 41%, the daily turnover rate was 66%, and the turnover was 999 billion yu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Jiu’an Medical announced on July 15 that it is expected that the net profit attributable to the parent in the first half of 2022 will be 11 billion yuan to 15 billion yuan, a year-on-year increase of 274636% to 28196
So, what kind of business is this? How to earn a lot of Jinpeng? According to the data, Jiu’an Medical is mainly engaged in the research and development, production and sales of health electronic products and smart hardwa.
The company focuses on the research and development, production and sales of household medical devices, as well as cloud platform systems and servic.
The main products are platforms for diabetic patients, and the main market is abro.
The self-test version of the antigen detection reagent developed by the company has successively obtained the certification of EU CE, German BfArM, Austrian BASG, Czech MZCR self-test whitelist, e.
, and can be sold in the above countri.
As for the reasons for the changes in performance in the first half of this year, Jiu'an Medical explained in the announcement that the company's iHealth kit products have obtained the FDA EUA authorization in the United States, and the company's own brand "iHealth" is used through the website of the US subsidiary and Amazon's US e-commerce platfo.
Carry out to C-side sales, and undertake government orders and commercial orders at the same ti.
Due to the substantial increase in the sales revenue of iHealth kit products during the reporting period, the company's performance during the reporting period also increased significantly compared with the same period last ye.
It is understood that on January 13 this year, iHealth LabsInc, a subsidiary of Jiu'an Medical, signed a "purchase contract" with ACC for Health kits, selling 250 million iHealth kit products to it, with a total contract price and tax of 275 billi.
US dollars (including shippin.
On January 26, iHealth US subsidiary signed a "Change Contract" with the American ACC on the original "Purchase Contrac.
On the basis of the purchase of 250 million iHealth kit products in the original contract, about 104 million additional iHealth kit products were purchas.
person, the total contract price and tax will increase by about 500 million US dollars (excluding freigh.
Driven by the antigen detection kit, the company achieved operating income of 2737 billion yuan in the first quarter of 2022, an increase of 66479% over the same period last year; net profit attributable to shareholders of listed companies was 1312 billion yuan, an increase of 375235% over the same period last ye.
According to statistics, the total profit of Jiu'an Medical in the past ten years (2012-2021) is only 940 million yuan, and the profit of Jiu'an Medical in one quarter of this year is about 15 times that of the total of the past ten yea.
In fact, it is not only the semi-annual and first quarter, but also the antigen detection kit product in the fourth quarter of 2021, which has enabled Jiu'an Medical to achieve a major reversal of its annual performan.
According to the financial report, Jiu’an Medical will achieve operating income of 397 billion yuan in 2021, a year-on-year increase of 136%; net profit attributable to shareholders of listed companies is 909 million yuan, a year-on-year increase of 279
Not long ago, Jiu'an Medical issued an announcement on the Shenzhen Stock Exchange's reply to the company's 2021 annual report inquiry lett.
The announcement shows that for the advantages compared with domestic and foreign companies in the same industry, Jiu'an Medical said that compared with domestic companies in the same industry, the company has advantages in access, brand and sales channels; compared with foreign companies in the same industry, the company It has large-scale supply capacity and marketing experience to C-end, and the production of the company's kits is domestic, which is more competitive in co.
Regarding the reasons for the high gross profit margin of the kit products and the commercial rationality, Jiu’an Medical stated that the iHealth kit product obtained the FDA EUA authorization in November 2021
There are fewer Chinese competitors in the North American market than in the European market, so companies can enjoy a certain access premi.
In addition, the company has formed a complete value chain from manufacturing to self-owned brand sales, with the iHealth brand premium advanta.
It is worth mentioning that the outbreak of the company's performance has also driven its stock price to rise all the w.
From November 1, 2021 to June 21, 2022, the share price of Jiu'an Medical rose 10176%, an increase of more than 10 tim.
As of the close on July 14, Jiu'an Medical's quotation was 651 yuan, an increase of 41%, the daily turnover rate was 66%, and the turnover was 999 billion yu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
